Unlocking More Blood Cancer Insights with NGS

Oncomine hemato-oncology research solutions

button_download-brochure-1

 

Elderly couple with their bikes

 

 


Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide1.

These challenging disorders are genetically complex, often harboring a range of somatic mutations. In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases.

 

Traditional molecular testing involves iterative single-analyte approaches, complex workflows, all of which results in variable, often lengthy, turnaround times.

Next-generation sequencing (NGS) has revolutionized the study of  hematologic malignancies by streamlining genetic profiling. NGS allows for efficient, simultaneous assessment of multiple genetic biomarkers with a single assay. Advancements in NGS automation enable results to now be available in as fast as 1-2 days.

 

 

Watch a brief video to see how the Ion Torrent Genexus System can deliver rapid results with minimal user intervention for myeloid samples. 

Hemato-oncology Research Solutions

Deepen your understanding of hematological malignancies with an unmatched offering of NGS testing solutions and capabilities. We offer a range of NGS assays for applications across a spectrum of disease research areas. Each assay is provided as part of a complete solution on our trusted NGS platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.

Integrated analysis software streamlines reporting and facilitates the interpretation of results. Unmatched workflow automation simplifies the testing process, enabling any laboratory to adopt NGS testing—including those without prior experience and expertise.

 

VIEW BROCHURE

Assay Menu

Customer Presentations:
Moving toward a brighter future in hemato-oncology 

Our customers and collaborators are making incredible research advancements, disrupting traditional paradigms, and bringing forth new insights and approaches for understanding hematologic malignancies. Our NGS technology has been embraced by some of the top minds in the world to address the most pressing challenges is these disease research areas.

Implementing NGS for the Study of Lymphoid Malignancies

Gerard Frigola, MD
Hematopathologist
Hospital Clinic, IDIBAPS,
University of Barcelona

heme-page-frigola

View Presentation

 

AMP 2023 Workshop On-Demand: NGS for Myeloid Malignancy Analysis

Cecilia Yeung, MD
Professor, Translational Science and Therapeutics Division
Medical Director, Fred Hutch Clinical Testing Labs
Fred Hutchinson Cancer Center

heme-page-yeung

View Presentation

 

Utility of NGS
in Lymphoid
Malignancies


Dr. Michael Krigstein
Consultant Haematologist
MBBS(Hons) FRACP FRCPA MCncrSc
SydPath, St Vincent’s Hospital

heme-page-krigstein

View Presentation

 

Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasm


Dr. John DeCoteau
Professor of Pathology & Laboratory Medicine, Medical Director, Advanced Diagnostic Research Laboratory, University of Saskatchewan

heme-customer-features-decoteau

View Presentation

 

How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms

 

Dr. Bevan Tandon
Director of Hematopathology and Molecular Pathology,
Pathline Labs

tandon2

View Presentation

 

Molecular Analysis in the Diagnosis and Prognosis of Hematological Malignancies

Gerard Frigola, MD
Hematopathologist
Hospital Clinic, IDIBAPS,
University of Barcelona

heme-page-menon

View Presentation

 

Additional Resources

Get in Touch

Request a quote or personal demonstration from a Thermo Fisher Representative.

button_request-contact

 

Sung H et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21660

 

For Research Use Only. Not for use in diagnostic procedures.